Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis

被引：4
|
作者：
Selvaraj, Shailendra, V [1 ]
Bares, Sara H. [2 ]
Havens, Joshua P. [1 ,2 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Pharm Practice, Omaha, NE USA
[2] Univ Nebraska Med Ctr, Dept Internal Med, Infect Dis, Omaha, NE USA
来源：
OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 10期
关键词：
emtricitabine/tenofovir alafenamide; pre-exposure prophylaxis; weight gain; DISOPROXIL FUMARATE; DOUBLE-BLIND; TENOFOVIR;
D O I：
10.1093/ofid/ofaa454
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We report a case of acute weight gain after switching from emtricitabine/tenofovir disoproxil to emtricitabine/tenofovir alafenamide for human immunodeficiency virus pre-exposure prophylaxis.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Human Immunodeficiency Virus Pre-Exposure Prophylaxis: Use of Emtricitabine/Tenofovir Alafenamide
    Blackwell, Christopher W.
    Castillo, Humberto Lopez
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2021, 17 (06): : 673 - 676
  • [2] Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo, Alexa B.
    Westmoreland, Drew A.
    Carneiro, Pedro B.
    Johnson, Jeremiah
    Grov, Christian
    AIDS PATIENT CARE AND STDS, 2021, 35 (08) : 327 - 334
  • [3] Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection
    Trang, Tracy P.
    Dong, Betty J.
    Kojima, Noah
    Klausner, Jeffrey D.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (09) : 1287 - 1294
  • [4] Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
    Kojima, Noah
    Klausner, Jeffrey D.
    OPEN FORUM INFECTIOUS DISEASES, 2016, 3 (01):
  • [5] Observed adherence-concentration benchmarks for emtricitabine/tenofovir alafenamide pre-exposure prophylaxis for African women
    Mugwanya, K.
    Mugo, N.
    Saina, M.
    Brown, C.
    Akelo, N.
    Schaafsma, T.
    Rechkina, E.
    Ngure, K.
    Mbugua, S.
    Hill, E.
    Chohan, B.
    Gichuru, E.
    Nzuve, P.
    Wu, L.
    Morrison, S.
    Rooney, J.
    Bushman, L.
    Anderson, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27
  • [6] Pre-exposure Prophylaxis Against Human Immunodeficiency Virus
    Cinar, Gule
    Birengel, Serhat
    FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, 2018, 23 (01): : 1 - 7
  • [7] HUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS: IS IT THE ANSWER?
    Kwong, Jeffrey
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2015, 11 (01): : 14 - 14
  • [8] Emtricitabine/tenofovir alafenamide usage in a Scottish sexual health service providing HIV pre-exposure prophylaxis: A service evaluation
    Burley, Nathan
    MacDonald, Rona
    Khan, Aafreen
    INTERNATIONAL JOURNAL OF STD & AIDS, 2024, 35 (04) : 308 - 310
  • [9] Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy
    Roelofsen, Eveline E.
    Wildenbeest, Sieds
    Mollema, Femke P.
    Burger, David M.
    AIDS, 2020, 34 (13) : 1989 - 1991
  • [10] Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine in clinical practice and the issues involved
    Bradshaw, H.
    HIV MEDICINE, 2018, 19 : S57 - S57
12345